- Home
- ARL vs ACRS Comparison
ARL vs ACRS Comparison
Compare ARL & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARL
- ACRS
- Stock Information
- Founded
- ARL 1999
- ACRS 2012
- Country
- ARL United States
- ACRS United States
- Employees
- ARL N/A
- ACRS N/A
- Industry
- ARL Building operators
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- ARL Real Estate
- ACRS Health Care
- Exchange
- ARL Nasdaq
- ACRS Nasdaq
- Market Cap
- ARL 245.7M
- ACRS 230.8M
- IPO Year
- ARL N/A
- ACRS 2015
- Fundamental
- Price
- ARL $15.39
- ACRS $2.72
- Analyst Decision
- ARL
- ACRS Strong Buy
- Analyst Count
- ARL 0
- ACRS 5
- Target Price
- ARL N/A
- ACRS $9.75
- AVG Volume (30 Days)
- ARL 1.9K
- ACRS 1.4M
- Earning Date
- ARL 11-06-2025
- ACRS 11-06-2025
- Dividend Yield
- ARL N/A
- ACRS N/A
- EPS Growth
- ARL N/A
- ACRS N/A
- EPS
- ARL 0.36
- ACRS N/A
- Revenue
- ARL $49,060,000.00
- ACRS $15,742,000.00
- Revenue This Year
- ARL N/A
- ACRS N/A
- Revenue Next Year
- ARL N/A
- ACRS N/A
- P/E Ratio
- ARL $43.16
- ACRS N/A
- Revenue Growth
- ARL N/A
- ACRS N/A
- 52 Week Low
- ARL $9.43
- ACRS $1.05
- 52 Week High
- ARL $18.00
- ACRS $4.24
- Technical
- Relative Strength Index (RSI)
- ARL 47.12
- ACRS 63.74
- Support Level
- ARL $14.95
- ACRS $2.34
- Resistance Level
- ARL $15.52
- ACRS $2.57
- Average True Range (ATR)
- ARL 0.33
- ACRS 0.24
- MACD
- ARL -0.10
- ACRS 0.02
- Stochastic Oscillator
- ARL 21.42
- ACRS 90.44
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.